ALEC
ALEC
Positions held
Your positionsALEC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
2026-10-06 · Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
2026-10-05 · Sector Update: Healthcare Stocks Advance Late Afternoon
2026-10-05 · Sector Update: Healthcare
2026-10-05 · Update: Alector Shares Rise After Licensing AL050 Program to Roche's Genentech
2026-10-05 · BC-Most Active Stocks
2026-10-05 · Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease Program
2026-10-05 · Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
2026-10-05 · Alector Licenses AL050 Program to Roche's Genentech
2026-09-03 · Alector to Participate in Upcoming Healthcare Conferences
Price (daily)
Full chart · RSI · MACD · patterns